Q203

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

A novel potent anti-tuberculosis agent targeting cytochrome b subunit qcrB, inhibits M. tuberculosis H37Rv with MIC50 of of 2.7 nM.

A novel potent anti-tuberculosis agent targeting cytochrome b subunit qcrB, inhibits M. tuberculosis H37Rv with MIC50 of of 2.7 nM; does not inhibit any of thecytochrome P450 (CYP450) isoenzymes; targets the respiratory cytochrome bc1 complex and triggers a rapid ATP depletion in M. tuberculosis, also inhibits the growth of MDR and XDR M. tuberculosis; deonstrates potency in mouse model of tuberculosis and displays pharmacokinetic and safety profiles.Bacterial Infection Phase 1 Clinical

Q-203;Q 203;IAP6;Telacebec

GPCR/G Protein

Antibacterial

MycobacteriumtuberculosisH37Rv

Infection

Bacterial Infection

1334719-95-7

557.01

C29H28ClF3N4O2

>98% (HPLC)

DMSO: 10 mM

CCC1=C(N2C=C(C=CC2=N1)Cl)C(=O)NCC3=CC=C(C=C3)N4CCC(CC4)C5=CC=C(C=C5)OC(F)(F)F

Imidazo[1,2-a]pyridine-3-carboxamide, 6-chloro-2-ethyl-N-[[4-[4-[4-(trifluoromethoxy)phenyl]-1-piperidinyl]phenyl]methyl]-

(-20℃)

With Ice Pack

≥ 2 years